The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Inclusion Criteria

• •Obtain of informed consent.
• •Histologically or cytologically confirmed non-small cell lung cancer.
• •World Health Organization (WHO) performance status (PS) of 0 to 2.
• •Measurable lesions as defined by RECIST criteria.
• •Second-line or more treatments.
• •Wild type of epidermal-growth-factor receptor (EGFR).
• •Life expectancy ≥12 weeks.
• •Organ functions normal, as defined below, within two weeks of randomization:
• •• Hb≥90g/L Absolute neutrophils count(ANC)≥1.5×109/L Platelets≥80×109/L Serum bilirubin≤2×ULN; Aspartate transaminase(AST) and alanine transaminase (ALT)≤2.5×ULN(≤5×ULN if liver metastases) Creatinine clearance≥45ml/min or Cr≤1.25×ULN.
• •Females of child-bearing potential must have negative serum pregnancy test.
• •Sexually active males and females (of childbearing potential) willing to practice contraception during the study.